Merck strikes historic deal with Trump admin to lower drug costs for Americans

EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe

Zydus receives FDA’s final approval for Verapamil Hydrochloride ER tablets

Texas hits Sanofi, Bristol-Myers Squibb with lawsuit over blood thinner drug efficacy

Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people

Ingenus Pharma launches first FDA-approved generic version of Premarin

Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo

FDA approves Alembic's Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients

TAHO Pharma submits NDA to FDA for world’s first Apixaban oral dissolving film

Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention